Monoclonal and engineered antibodies for human parenteral clinical use: regulatory considerations
- 1 January 1992
- journal article
- Published by Elsevier in Trends in Biotechnology
- Vol. 10 (9) , 305-309
- https://doi.org/10.1016/0167-7799(92)90255-t
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- [19] Rapid and efficient site-specific mutagenesis without phenotypic selectionPublished by Elsevier ,2004
- ANTI-CD3 MURINE MONOCLONAL ISOTYPE SWITCH VARIANTS TESTED FOR TOXICITY AND IMMUNOLOGIC MONITORING IN FOUR CHIMPANZEESTransplantation, 1990
- IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATIONTransplantation, 1990
- Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage LambdaScience, 1989
- Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coliNature, 1989
- Functional Expression of Human Monoclonal Antibody Genes Directed Against Pseudomonal Exotoxin A in Mouse Myeloma CellsNature Biotechnology, 1989
- Reshaping human antibodies for therapyNature, 1988
- Reconstitution of functionally active antibody directed against creatine kinase from separately expressed heavy and light chains in non-lymphoid cellsGene, 1987
- Production of functional chimaeric mouse/human antibodyNature, 1984
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975